NCT06547099Recruiting
Study to Understand Novel Biomarkers in Researching Dementia
Blood Amyloid, Tau, and Neurodegeneration Biomarkers and Prediction of Clinical Onset, Cognitive Decline, and Dementia Diagnosis
Source: ClinicalTrials.gov · Last updated 11 Sept 2026
Brief summary (registry, in English)
The purpose of this study is to determine the relationships between amyloid, tau, and neurodegeneration biomarkers in the blood and the presence of Alzheimer's disease (AD) pathology, clinical cognitive decline, and diagnosis. We aim to understand how well blood-based biomarkers can diagnose and predict Alzheimer's disease, which will help to further develop and validate blood tests for the disease.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1800 (estimated)
- First submitted
- 1 Aug 2024
- Start date
- 14 Aug 2024
- Primary completion date
- Dec 2028
- Lead sponsor
- Washington University School of Medicine
- Diseases
- Alzheimer disease
- NCT number
- NCT06547099
What you commit to
- Study type: Observational
- Planned participants: 1800
- From 14 Aug 2024 to the primary completion date, Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Unable to perform one or more basic activities of daily living (eating, bathing, dressing, ambulating, toileting) due to cognitive impairment
- Uncontrolled hepatitis B, hepatitis C, or HIV at time of blood collection
- Taking a disease-modifying drug for AD at time of enrollment
Other
- Blood transfusion in the last three months
- Unwilling or unable to participate in all study activities
Who the study is looking for
- At least 60 years of age
- 80% of the newly enrolled clinic-based cohort will have symptoms of forgetfulness, mild cognitive impairment, mild dementia, or Alzheimer's disease as determined by their medical chart and/or provider
- All SEABIRD participants will be invited to participate regardless of their cognitive status
Age in the registry: 60 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Washington University School of Medicine Coordinator of this site? Confirm its status | St Louis | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.